This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cascinu, S. Articles by Catalano, G. Search for Related Content PubMed PubMed Citation Articles by Cascinu, S. Articles by Catalano, G.

Expression of Vascular Endothelial Growth Factor Can Predict Event-free Survival in Stage II Colon Cancer

Istituto di Oncologia, Università degli Studi di Messina, 98125 Messina [S. C.]; Unità Operativa di Anatomia Patologica [M. P. S., P. M.] and Unità Operativa di Oncologia Medica [P. G., V. C., C. R., A. M. B., F. G., G. C.], Azienda Ospedaliera "Ospedale S. Salvatore," 61100 Pesaro; Divisione di Oncologia Medica, Azienda Ospedali Riuniti, 89100 Reggio Calabria [G. G.]; and Clinica di Semeiotica Chirurgica, Università degli Studi di Ancona, 60100 Ancona [R. G., V. S.]; Italy

The usefulness of chemotherapy in patients with stage II disease continues to be debated. Biological prognostic factors may allow further insight into the optimal treatment strategy for patients with node-negative disease. Vascular endothelial growth factor (VEGF) seems to be essential for angiogenesis and for the growth of colorectal cancer. Recently, it was shown able to predict disease recurrence in patients with stage II colon cancer. Specimens of surgically resected colon cancer were immunostained for VEGF. Consecutive patients referred to the study institutions were considered eligible for this study. The main inclusion criteria were stage II tumor, sufficient tumor material, and adequate follow-up information. Analysis was performed on 121 patients. The recurrence rate in the patients with VEGF-positive tumors was 50% (18 of 36 patients), which was significantly higher than that observed in patients with VEGF-negative tumors [11.7% (10 of 85 patients); P = 0.001]. Also the degree of VEGF immunoreactivity was significantly higher in 28 relapsing patients compared with 93 disease-free patients (mean VEGF score, 2.84 ± 0.38 versus 0.66 ± 0.17; P = 0.0001). VEGF may be used in a clinical setting to identify patients at high risk for relapse who may benefit from adjuvant treatment including new therapeutic strategies such as monoclonal antibody neutralizing VEGF.

This article has been cited by other articles:

				J Heidemann, D G Binion, W Domschke, and T Kucharzik Antiangiogenic therapy in human gastrointestinal malignancies. Gut, October 1, 2006; 55(10): 1497 - 1511. [Full Text] [PDF]

				C.-C. Chang, M.-T. Lin, B.-R. Lin, Y.-M. Jeng, S.-T. Chen, C.-Y. Chu, R. J. Chen, K.-J. Chang, P.-C. Yang, and M.-L. Kuo Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst, July 19, 2006; 98(14): 984 - 995. [Abstract] [Full Text] [PDF]

				T. Troiani, O. Lockerbie, M. Morrow, F. Ciardiello, and S. G. Eckhardt Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol. Cancer Ther., July 1, 2006; 5(7): 1883 - 1894. [Abstract] [Full Text] [PDF]

				A. L. Mulkeen, T. Silva, P. S. Yoo, J. C. Schmitz, E. Uchio, E. Chu, and C. Cha Short Interfering RNA-Mediated Gene Silencing of Vascular Endothelial Growth Factor: Effects on Cellular Proliferation in Colon Cancer Cells Arch Surg, April 1, 2006; 141(4): 367 - 374. [Abstract] [Full Text] [PDF]

				E. K. Bergsland When Does the Presence of the Target Predict Response to the Targeted Agent? J. Clin. Oncol., January 10, 2006; 24(2): 213 - 216. [Full Text] [PDF]

				H. Muguruma, S. Yano, S. Kakiuchi, H. Uehara, M. Kawatani, H. Osada, and S. Sone Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity Clin. Cancer Res., December 15, 2005; 11(24): 8822 - 8828. [Abstract] [Full Text] [PDF]

				W. L. Allen and P. G. Johnston Role of Genomic Markers in Colorectal Cancer Treatment J. Clin. Oncol., July 10, 2005; 23(20): 4545 - 4552. [Abstract] [Full Text] [PDF]

				A. Zaniboni and R. Labianca Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann. Onc., September 1, 2004; 15(9): 1310 - 1318. [Abstract] [Full Text] [PDF]

				O. Stoeltzing, M. F. McCarty, J. S. Wey, F. Fan, W. Liu, A. Belcheva, C. D. Bucana, G. L. Semenza, and L. M. Ellis Role of Hypoxia-Inducible Factor 1{alpha} in Gastric Cancer Cell Growth, Angiogenesis, and Vessel Maturation J Natl Cancer Inst, June 16, 2004; 96(12): 946 - 956. [Abstract] [Full Text] [PDF]

				N. Garcia de la Torre, I. Buley, J. A. H. Wass, D. G. Jackson, and H. E. Turner Angiogenesis and Lymphangiogenesis in Parathyroid Proliferative Lesions J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2890 - 2896. [Abstract] [Full Text] [PDF]

				G. Galizia, E. Lieto, F. Ferraraccio, M. Orditura, F. De Vita, P. Castellano, V. Imperatore, C. Romano, F. Ciardiello, B. Agostini, et al. Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas Clin. Cancer Res., May 15, 2004; 10(10): 3490 - 3499. [Abstract] [Full Text] [PDF]

				A M Jubb, T Q Pham, A M Hanby, G D Frantz, F V Peale, T D Wu, H W Koeppen, and K J Hillan Expression of vascular endothelial growth factor, hypoxia inducible factor 1{alpha}, and carbonic anhydrase IX in human tumours J. Clin. Pathol., May 1, 2004; 57(5): 504 - 512. [Abstract] [Full Text] [PDF]

				F. Graziano and S. Cascinu Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann. Onc., July 1, 2003; 14(7): 1026 - 1038. [Abstract] [Full Text] [PDF]

				H. F. Dvorak Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380. [Abstract] [Full Text] [PDF]

				A. Takeda, O. Stoeltzing, S. A. Ahmad, N. Reinmuth, W. Liu, A. Parikh, F. Fan, M. Akagi, and L. M. Ellis Role of Angiogenesis in the Development and Growth of Liver Metastasis Ann. Surg. Oncol., August 1, 2002; 9(7): 610 - 616. [Abstract] [Full Text] [PDF]

				S. Kinuya, A. Kawashima, K. Yokoyama, K. Koshida, S. Konishi, N. Watanabe, N. Shuke, H. Bunko, T. Michigishi, and N. Tonami Cooperative Effect of Radioimmunotherapy and Antiangiogenic Therapy with Thalidomide in Human Cancer Xenografts J. Nucl. Med., August 1, 2002; 43(8): 1084 - 1089. [Abstract] [Full Text] [PDF]

				C. Pellizzaro, D. Coradini, and M. G. Daidone Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29 Carcinogenesis, May 1, 2002; 23(5): 735 - 740. [Abstract] [Full Text] [PDF]